Meibomian Gland Dysfunction (MGD)
6
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction
Effectiveness of Low Level Light Therapy and Intense Pulse Light on Mite Count as Adjuntive Therapies in Demodex Blepharitis Using Artificial Intelligent Program (Ai-Demodex)
An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
The Effect of an Eyelid Warming Device for the Management of Meibomian Gland Dysfunction
Treatment of Meibomian Gland Dysfunction